Zacks Investment Research
22 May 2026, 16:11 UTC · 24w ago
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Impact · against what's priced in
Keros Therapeutics faces negative pressure following a significant Q1 miss on both earnings and revenue. While a leaner expense base and extended cash runway provide some stability, the volatility of its milestone-based revenue model remains a primary risk.
- KROS−0.40
No priced-in read yet
- In context
The company missed Q1 expectations with a $1.21 loss per share against a $0.92 estimate and revenue of $0.4 million versus a $4 million estimate. A leaner expense base and longer cash runway offer a partial offset to the steep 99.8% year-over-year revenue decline.
Read from the article alone
Search tags
